Dimension Therapeutics Inc to Post FY2017 Earnings of ($2.12) Per Share, Cantor Fitzgerald Forecasts (DMTX)

Dimension Therapeutics Inc (NASDAQ:DMTX) – Analysts at Cantor Fitzgerald boosted their FY2017 EPS estimates for Dimension Therapeutics in a note issued to investors on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst E. Piros now anticipates that the biotechnology company will earn ($2.12) per share for the year, up from their prior estimate of ($3.00). Cantor Fitzgerald currently has a “Hold” rating and a $3.00 target price on the stock.

Other research analysts have also issued reports about the stock. Canaccord Genuity set a $20.00 target price on shares of Dimension Therapeutics and gave the company a “buy” rating in a report on Saturday, March 11th. Jefferies Group LLC restated a “buy” rating and issued a $7.00 target price on shares of Dimension Therapeutics in a report on Thursday, February 2nd. Finally, Zacks Investment Research upgraded shares of Dimension Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $8.35.

Earnings History and Estimates for Dimension Therapeutics (NASDAQ:DMTX)

COPYRIGHT VIOLATION NOTICE: “Dimension Therapeutics Inc to Post FY2017 Earnings of ($2.12) Per Share, Cantor Fitzgerald Forecasts (DMTX)” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/04/21/fy2017-eps-estimates-for-dimension-therapeutics-inc-increased-by-analyst-dmtx-updated-updated.html.

Dimension Therapeutics (NASDAQ:DMTX) traded down 3.33% during trading on Thursday, reaching $1.45. 31,651 shares of the company’s stock traded hands. The stock’s market cap is $36.31 million. Dimension Therapeutics has a one year low of $1.35 and a one year high of $10.47. The firm’s 50 day moving average price is $1.74 and its 200-day moving average price is $3.77.

Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings data on Thursday, March 9th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.03. The business had revenue of $4.10 million for the quarter, compared to the consensus estimate of $3.04 million. Dimension Therapeutics had a negative net margin of 464.39% and a negative return on equity of 50.07%.

Several hedge funds and other institutional investors have recently made changes to their positions in DMTX. New Leaf Venture Partners L.L.C. bought a new position in shares of Dimension Therapeutics during the fourth quarter valued at $8,958,000. Baker BROS. Advisors LP bought a new position in shares of Dimension Therapeutics during the third quarter valued at $10,003,000. State Street Corp raised its position in shares of Dimension Therapeutics by 37.2% in the fourth quarter. State Street Corp now owns 186,544 shares of the biotechnology company’s stock valued at $812,000 after buying an additional 50,570 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Dimension Therapeutics during the fourth quarter valued at $236,000. Finally, Turner Investments LLC bought a new position in shares of Dimension Therapeutics during the fourth quarter valued at $131,000. Institutional investors and hedge funds own 85.43% of the company’s stock.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Get a free copy of the Zacks research report on Dimension Therapeutics (DMTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Dimension Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dimension Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit